文献速递呼吸道感染呼吸危重症与机械通气

GPR183拮抗减轻流感与SARS-CoV-2感染中的巨噬细胞浸润

GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection.
PubMed 文献 · Eur Respir J · 2023-03-09

本研究在甲型流感病毒和SARS-CoV-2感染的小鼠模型中,发现氧化胆固醇及其受体GPR183驱动单核/巨噬细胞向肺内浸润。Gpr183功能缺失突变或GPR183拮抗剂治疗可减少巨噬细胞浸润和炎性细胞因子产生,拮抗剂还显著减轻SARS-CoV-2感染严重程度并降低病毒载量。COVID-19患者支气管肺泡灌洗液单细胞RNA测序显示巨噬细胞中CH25H、CYP7B1和GPR183显著上调。

要点

  • 氧化胆固醇-GPR183轴驱动病毒性呼吸道感染时肺内巨噬细胞浸润。
  • GPR183拮抗剂在SARS-CoV-2小鼠模型中减轻病情严重程度并降低病毒载量。
  • COVID-19患者肺泡巨噬细胞中CH25H、CYP7B1和GPR183显著上调。

核心结论

  • 氧化胆固醇通过GPR183驱动肺部炎症,靶向GPR183在严重病毒性呼吸道感染中具有治疗获益的临床前证据。

研究设计与样本

  • 临床前小鼠模型研究,采用甲型流感病毒和SARS-CoV-2感染模型,并分析健康对照与中、重度COVID-19患者支气管肺泡灌洗液的单细胞RNA测序数据。

主要发现

  • IAV和SARS-CoV-2感染均上调肺内CH25H和CYP7B1,局部产生25-OHC和7α,25-OHC。
  • Gpr183功能缺失突变或GPR183拮抗剂治疗减少IAV或SARS-CoV-2感染小鼠肺内巨噬细胞浸润和炎性细胞因子产生。
  • GPR183拮抗剂显著减轻SARS-CoV-2感染严重程度并降低病毒载量。
  • COVID-19患者(中度及重度)巨噬细胞中CH25H、CYP7B1和GPR183显著上调。

临床怎么用

  • 提示GPR183可作为严重病毒性呼吸道感染抗炎治疗的潜在靶点,尚需临床研究验证。

局限性

  • 证据来自临床前小鼠模型及患者样本的单细胞RNA测序分析,尚缺乏人体干预研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Severe viral respiratory infections are often characterised by extensive myeloid cell infiltration and activation and persistent lung tissue injury. However, the immunological mechanisms driving excessive inflammation in the lung remain poorly understood. OBJECTIVES: To identify the mechanisms that drive immune cell recruitment in the lung during viral respiratory infections and identify novel drug targets to reduce inflammation and disease severity. METHODS: Preclinical murine models of influenza A virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. RESULTS: Oxidised cholesterols and the oxysterol-sensing receptor GPR183 were identified as drivers of monocyte/macrophage infiltration to the lung during influenza A virus (IAV) and SARS-CoV-2 infection. Both IAV and SARS-CoV-2 infection upregulated the enzymes cholesterol 25-hydroxylase (CH25H) and cytochrome P450 family 7 subfamily member B1 (CYP7B1) in the lung, resulting in local production of the oxidised cholesterols 25-hydroxycholesterol (25-OHC) and 7α,25-dihydroxycholesterol (7α,25-OHC). Loss-of-function mutation of Gpr183 or treatment with a GPR183 antagonist reduced macrophage infiltration and inflammatory cytokine production in the lungs of IAV- or SARS-CoV-2-infected mice. The GPR183 antagonist significantly attenuated the severity of SARS-CoV-2 infection and viral loads. Analysis of single-cell RNA-sequencing data on bronchoalveolar lavage samples from healthy controls and COVID-19 patients with moderate and severe disease revealed that CH25H, CYP7B1 and GPR183 are significantly upregulated in macrophages during COVID-19. CONCLUSION: This study demonstrates that oxysterols drive inflammation in the lung via GPR183 and provides the first preclinical evidence for the therapeutic benefit of targeting GPR183 during severe viral respiratory infections.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Foo CX, Bartlett S, Chew KY, et al. GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. Eur Respir J. 2023. PMID: 36396144. doi:10.1183/13993003.01306-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。